Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewcelX ( (NCEL) ) just unveiled an announcement.
On February 12, 2026, NewcelX announced a peer-reviewed review article in Clinical Drug Investigation analyzing Mazindol immediate-release/sustained-release (IR/SR), highlighting a 50-year mechanism-of-action legacy and more than 20 years of research supporting its extended-release (ER) formulation. The publication underscores Mazindol ER’s differentiated, de-risked CNS profile aimed at large underserved markets such as narcolepsy, ADHD, and substance use disorders, with intellectual property dating back to 2006.
NewcelX said the article provides independent third-party validation of Mazindol ER’s clinical and mechanistic profile, strengthening the asset’s position within its Contingent Value Right framework tied to potential proceeds from legacy assets. Management reported it is in advanced, competitive discussions with multiple parties over potential licensing or acquisition of Mazindol ER, a process the company believes could enhance CVR value realization, bolster its CNS pipeline, and improve strategic positioning for shareholders and CVR holders.
More about NewcelX
NewcelX Ltd. is a clinical-stage biopharmaceutical company based in Zurich that develops stem-cell-derived therapies for Type 1 diabetes. Its lead program, IsletRx, uses a human pluripotent stem cell platform to create off-the-shelf cell replacement therapies, integrating immune protection and translational science to target major unmet needs in diabetes care.
Average Trading Volume: 119,247
Technical Sentiment Signal: Sell
Current Market Cap: $13.17M
See more data about NCEL stock on TipRanks’ Stock Analysis page.